Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 3, 2012, Pages 327-334

  Oliva, S ^a   Di Nardo, G ^a   Ferrari, F ^a   Mallardo, S ^a   Rossi, P ^a   Patrizi, G ^a   Cucchiara, S ^a   Stronati, L ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ENEA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESALAZINE; PLACEBO; PROBIOTIC AGENT; REUFLOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LACTOBACILLUS REUTERI; MALE; MAYO SCORE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; RECTUM MUCOSA; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, RECTAL; ADOLESCENT; CHILD; COLITIS, ULCERATIVE; CYTOKINES; DOUBLE-BLIND METHOD; ENEMA; FEMALE; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS REUTERI; MALE; PROBIOTICS; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84855355717     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04939.x     Document Type: Article

References (40)

1. Glick SR, Carvalho RS,. Inflammatory bowel disease. Pediatr Rev 2011; 32: 14-24.
2. Griffiths AM,. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004; 18: 509-23. (Pubitemid 38667463)
3. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34. (Pubitemid 47123518)
4. De Vroey B, Colombel JF,. IBD in 2010: optimizing treatment and minimizing adverse events. Nat Rev Gastroenterol Hepatol 2011; 8: 74-6.
5. Wilson DC, Thomas AG, Croft NM, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010; 50: S14-34.
6. Dupont AW, Dupont HL,. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8: 523-31.
7. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11: 7.
8. Fava F, Danese S,. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 2011; 17: 557-66.
9. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-7. (Pubitemid 44893575)
10. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54. (Pubitemid 34049193)
11. Chassaing B, Darfeuille-Michaud A,. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-28.
12. Negroni A, Costanzo M, Vitali R, et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011 [Epub ahead of print].
13. Gerritsen J, Smidt H, Rijkers GT, et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011; 6: 209-40.
14. Yoon SS, Sun J,. Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract 2011; 2011: 971938.
15. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-82. (Pubitemid 350275869)
16. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-9. (Pubitemid 41368272)
17. Huynh HQ, de Bruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009; 15: 760-8.
18. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-43.
19. Guandalini S,. Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6: 47-54.
20. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
21. Bousvaros A, Antonioli DA, Colletti RB, et al., North American Society for Pediatric Gastroenterology, Hepatology and Nutrition; Colitis Foundation of America. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-74.
22. Florén CH, Benoni C, Willén R, et al. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-62. (Pubitemid 17078540)
23. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
24. Bloom SM, Bijanki VN, Nava GM, et al. Commensal bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 2011; 9: 390-403.
25. Ballal SA, Gallini CA, Segata N, et al. Host and gut microbiota symbiotic factors: lessons from inflammatory bowel disease and successful symbionts. Cell Microbiol 2011; 13: 508-17.
26. Baker PI, Love DR, Ferguson LR,. Role of gut microbiota in Crohn's disease. Expert Rev Gastroenterol Hepatol 2009; 3: 535-46.
27. Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007; 119: 124-30.
28. Miniello VL, Brunetti L, Tesse R, et al. Lactobacillus reuteri modulates cytokines production in exhaled breath condensate of children with atopic dermatitis. J Pediatr Gastroenterol Nutr 2010; 50: 573-6.
29. Indrio F, Riezzo G, Raimondi F, et al. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 2008; 152: 801-6.
30. Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004; 70: 1176-81. (Pubitemid 38568246)
31. Liu Y, Fatheree NY, Mangalat N, et al. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1087-96.
32. Livingston M, Loach D, Wilson M, et al. Gut commensal Lactobacillus reuteri 100-23 stimulates an immunoregulatory response. Immunol Cell Biol 2010; 88: 99-102.
33. Stronati L, Negroni A, Merola P, et al. Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease. Inflamm Bowel Dis 2008; 14: 295-302. (Pubitemid 351441316)
34. Kucharzik T, Hudson JT 3rd, Lügering A, et al. Acute induction of human IL-8 production by intestinal epithelium triggers neutrophil infiltration without mucosal injury. Gut 2005; 54: 1565-72. (Pubitemid 41531772)
35. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1882-90.
36. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-45.
37. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK,. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-88.
38. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119: 1473-82. (Pubitemid 32198672)
39. Reiff C, Kelly D,. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010; 300: 25-33.
40. Gareau MG, Sherman PM, Walker WA,. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010; 7: 503-14.